On November 22, 2022, GlaxoSmithKline decided to voluntarily withdraw the Biologic License Application (BLA) for Blenrep® (belantamab mafodotin-blmf).
How does this affect our members?
GlaxoSmithKline will send letters to providers who prescribe Blenrep to notify them about this decision. These letters will include information about the compassionate use of Blenrep for individuals who are currently receiving the drug. AmeriHealth HMO, Inc., AmeriHealth Insurance Company of New Jersey, and AmeriHealth Administrators (collectively, AmeriHealth) will continue to cover Blenrep for these members. New requests for Blenrep will not be covered by AmeriHealth.
For more information
The complete statement on the U.S. market withdrawal of Blenrep, including details about the compassionate use program, is available on the GlaxoSmithKline website.